Online inquiry

IVTScrip™ mRNA-Human ARF1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK28563MR)

This product GTTS-WK28563MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARF1 protein. This product can be used in CD141+CLEC9A+ dendritic cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001024226.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 375
UniProt ID P84077
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARF1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK28563MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK0318MR IVTScrip™ mRNA-Human SOST, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SOST
GTTS-WK24085MR IVTScrip™ mRNA-Human ARHGAP18, (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARHGAP18
GTTS-WK26788MR IVTScrip™ mRNA-Human ARHGAP23, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP23
GTTS-WK11173MR IVTScrip™ mRNA-Human ABI1, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABI1
GTTS-WK8300MR IVTScrip™ mRNA-Human ADAMTS16, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADAMTS16
GTTS-WK8995MR IVTScrip™ mRNA-Human AGC1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGC1
GTTS-WK21264MR IVTScrip™ mRNA-Human ANXA6, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANXA6
GTTS-WK20610MR IVTScrip™ mRNA-Human ANKRD20A9P, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ANKRD20A9P
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW